Literature DB >> 22147379

Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 25 weeks' gestation.

Waldemar A Carlo1, Scott A McDonald, Avroy A Fanaroff, Betty R Vohr, Barbara J Stoll, Richard A Ehrenkranz, William W Andrews, Dennis Wallace, Abhik Das, Edward F Bell, Michele C Walsh, Abbot R Laptook, Seetha Shankaran, Brenda B Poindexter, Ellen C Hale, Nancy S Newman, Alexis S Davis, Kurt Schibler, Kathleen A Kennedy, Pablo J Sánchez, Krisa P Van Meurs, Ronald N Goldberg, Kristi L Watterberg, Roger G Faix, Ivan D Frantz, Rosemary D Higgins.   

Abstract

CONTEXT: Current guidelines, initially published in 1995, recommend antenatal corticosteroids for mothers with preterm labor from 24 to 34 weeks' gestational age, but not before 24 weeks due to lack of data. However, many infants born before 24 weeks' gestation are provided intensive care.
OBJECTIVE: To determine if use of antenatal corticosteroids is associated with improvement in major outcomes for infants born at 22 and 23 weeks' gestation. DESIGN, SETTING, AND PARTICIPANTS: Cohort study of data collected prospectively on inborn infants with a birth weight between 401 g and 1000 g (N = 10,541) born at 22 to 25 weeks' gestation between January 1, 1993, and December 31, 2009, at 23 academic perinatal centers in the United States. Certified examiners unaware of exposure to antenatal corticosteroids performed follow-up examinations on 4924 (86.5%) of the infants born between 1993 and 2008 who survived to 18 to 22 months. Logistic regression models generated adjusted odds ratios (AORs), controlling for maternal and neonatal variables. MAIN OUTCOME MEASURES: Mortality and neurodevelopmental impairment at 18 to 22 months' corrected age.
RESULTS: Death or neurodevelopmental impairment at 18 to 22 months was significantly lower for infants who had been exposed to antenatal corticosteroids and were born at 23 weeks' gestation (83.4% with exposure to antenatal corticosteroids vs 90.5% without exposure; AOR, 0.58 [95% CI, 0.42-0.80]), at 24 weeks' gestation (68.4% with exposure to antenatal corticosteroids vs 80.3% without exposure; AOR, 0.62 [95% CI, 0.49-0.78]), and at 25 weeks' gestation (52.7% with exposure to antenatal corticosteroids vs 67.9% without exposure; AOR, 0.61 [95% CI, 0.50-0.74]) but not in those infants born at 22 weeks' gestation (90.2% with exposure to antenatal corticosteroids vs 93.1% without exposure; AOR, 0.80 [95% CI, 0.29-2.21]). If the mothers had received antenatal corticosteroids, the following events occurred significantly less in infants born at 23, 24, and 25 weeks' gestation: death by 18 to 22 months; hospital death; death, intraventricular hemorrhage, or periventricular leukomalacia; and death or necrotizing enterocolitis. For infants born at 22 weeks' gestation, the only outcome that occurred significantly less was death or necrotizing enterocolitis (73.5% with exposure to antenatal corticosteroids vs 84.5% without exposure; AOR, 0.54 [95% CI, 0.30-0.97]).
CONCLUSION: Among infants born at 23 to 25 weeks' gestation, antenatal exposure to corticosteroids compared with nonexposure was associated with a lower rate of death or neurodevelopmental impairment at 18 to 22 months.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22147379      PMCID: PMC3565238          DOI: 10.1001/jama.2011.1752

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  27 in total

1.  Antenatal glucocorticoid treatment decreases mortality and chronic lung disease in survivors among 23- to 28-week gestational age preterm infants.

Authors:  José Figueras-Aloy; Manuel Moro Serrano; Jesús Pérez Rodríguez; Cristina Fernández Pérez; Vicente Roqués Serradilla; José Quero Jiménez; Rafael Jiménez González
Journal:  Am J Perinatol       Date:  2005-11       Impact factor: 1.862

2.  Prenatal corticosteroids--early gain, long-term questions.

Authors:  Alan D Stiles
Journal:  N Engl J Med       Date:  2007-09-20       Impact factor: 91.245

3.  Antenatal corticosteroids promote survival of extremely preterm infants born at 22 to 23 weeks of gestation.

Authors:  Rintaro Mori; Satoshi Kusuda; Masanori Fujimura
Journal:  J Pediatr       Date:  2011-02-22       Impact factor: 4.406

4.  Neurodevelopmental outcomes of extremely low birth weight infants <32 weeks' gestation between 1993 and 1998.

Authors:  Betty R Vohr; Linda L Wright; W Kenneth Poole; Scott A McDonald
Journal:  Pediatrics       Date:  2005-09       Impact factor: 7.124

Review 5.  Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth.

Authors:  D Roberts; S Dalziel
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

6.  Long-term outcomes after repeat doses of antenatal corticosteroids.

Authors:  Ronald J Wapner; Yoram Sorokin; Lisa Mele; Francee Johnson; Donald J Dudley; Catherine Y Spong; Alan M Peaceman; Kenneth J Leveno; Fergal Malone; Steve N Caritis; Brian Mercer; Margaret Harper; Dwight J Rouse; John M Thorp; Susan Ramin; Marshall W Carpenter; Steven G Gabbe
Journal:  N Engl J Med       Date:  2007-09-20       Impact factor: 91.245

7.  Outcomes at 2 years of age after repeat doses of antenatal corticosteroids.

Authors:  Caroline A Crowther; Lex W Doyle; Ross R Haslam; Janet E Hiller; Jane E Harding; Jeffrey S Robinson
Journal:  N Engl J Med       Date:  2007-09-20       Impact factor: 91.245

8.  Effect of antenatal corticosteroids on survival for neonates born at 23 weeks of gestation.

Authors:  Edward J Hayes; David A Paul; Gary E Stahl; Jolene Seibel-Seamon; Kevin Dysart; Benjamin E Leiby; Amy B Mackley; Vincenzo Berghella
Journal:  Obstet Gynecol       Date:  2008-04       Impact factor: 7.661

9.  Neurodevelopmental outcomes of extremely low birth weight infants exposed prenatally to dexamethasone versus betamethasone.

Authors:  Ben H Lee; Barbara J Stoll; Scott A McDonald; Rosemary D Higgins
Journal:  Pediatrics       Date:  2008-02       Impact factor: 7.124

10.  The EPICure study: associations and antecedents of neurological and developmental disability at 30 months of age following extremely preterm birth.

Authors:  N S Wood; K Costeloe; A T Gibson; E M Hennessy; N Marlow; A R Wilkinson
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-03       Impact factor: 5.747

View more
  85 in total

1.  Approach to infants born at 22 to 24 weeks' gestation: relationship to outcomes of more-mature infants.

Authors:  P Brian Smith; Namasivayam Ambalavanan; Lei Li; C Michael Cotten; Matthew Laughon; Michele C Walsh; Abhik Das; Edward F Bell; Waldemar A Carlo; Barbara J Stoll; Seetha Shankaran; Abbot R Laptook; Rosemary D Higgins; Ronald N Goldberg
Journal:  Pediatrics       Date:  2012-05-28       Impact factor: 7.124

Review 2.  Advocating for equality for preterm infants.

Authors:  Daniel Batton; Beau Batton
Journal:  CMAJ       Date:  2013-10-28       Impact factor: 8.262

3.  Survival and Neurodevelopmental Outcomes among Periviable Infants.

Authors:  Noelle Younge; Ricki F Goldstein; Carla M Bann; Susan R Hintz; Ravi M Patel; P Brian Smith; Edward F Bell; Matthew A Rysavy; Andrea F Duncan; Betty R Vohr; Abhik Das; Ronald N Goldberg; Rosemary D Higgins; C Michael Cotten
Journal:  N Engl J Med       Date:  2017-02-16       Impact factor: 91.245

4.  Non-Invasive Ventilation in Neonatology.

Authors:  Judith Behnke; Brigitte Lemyre; Christoph Czernik; Klaus-Peter Zimmer; Harald Ehrhardt; Markus Waitz
Journal:  Dtsch Arztebl Int       Date:  2019-03-08       Impact factor: 5.594

5.  Association of Short Antenatal Corticosteroid Administration-to-Birth Intervals With Survival and Morbidity Among Very Preterm Infants: Results From the EPICE Cohort.

Authors:  Mikael Norman; Aurelie Piedvache; Klaus Børch; Lene Drasbek Huusom; Anna-Karin Edstedt Bonamy; Elizabeth A Howell; Pierre-Henri Jarreau; Rolf F Maier; Ole Pryds; Liis Toome; Heili Varendi; Tom Weber; Emilija Wilson; Arno Van Heijst; Marina Cuttini; Jan Mazela; Henrique Barros; Patrick Van Reempts; Elizabeth S Draper; Jennifer Zeitlin
Journal:  JAMA Pediatr       Date:  2017-07-01       Impact factor: 16.193

6.  Perinatal factors associated with active intensive treatment at the border of viability: a population-based study.

Authors:  I Litmanovitz; B Reichman; S Arnon; V Boyko; L Lerner-Geva; S Bauer-Rusak; T Dolfin
Journal:  J Perinatol       Date:  2015-05-14       Impact factor: 2.521

7.  Bronchopulmonary Dysplasia: Executive Summary of a Workshop.

Authors:  Rosemary D Higgins; Alan H Jobe; Marion Koso-Thomas; Eduardo Bancalari; Rose M Viscardi; Tina V Hartert; Rita M Ryan; Suhas G Kallapur; Robin H Steinhorn; Girija G Konduri; Stephanie D Davis; Bernard Thebaud; Ronald I Clyman; Joseph M Collaco; Camilia R Martin; Jason C Woods; Neil N Finer; Tonse N K Raju
Journal:  J Pediatr       Date:  2018-03-16       Impact factor: 4.406

Review 8.  An update on pharmacologic approaches to bronchopulmonary dysplasia.

Authors:  Sailaja Ghanta; Kristen Tropea Leeman; Helen Christou
Journal:  Semin Perinatol       Date:  2013-04       Impact factor: 3.300

9.  Neonatal outcomes of very preterm infants from a neonatal intensive care center.

Authors:  Wei-Qin Zhou; Ya-Bo Mei; Xiao-Ying Zhang; Qiu-Ping Li; Xiang-Yong Kong; Zhi-Chun Feng
Journal:  World J Pediatr       Date:  2014-01-25       Impact factor: 2.764

Review 10.  Antenatal corticosteroids for periviable birth.

Authors:  Ronald J Wapner
Journal:  Semin Perinatol       Date:  2013-12       Impact factor: 3.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.